Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy

Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy: a Randomized Controlled Clinical Study

It is demonstrated that remote ischemic preconditioning can alleviate the degree of acute renal injury on the operated side in patients undergoing partial nephrectomy.

Study Overview

• Status: Not yet recruiting
• Conditions: Renal Cell Carcinoma (RCC); Renal Function Abnormal
• Intervention / Treatment: Procedure: Ischemic preconditioning; Procedure: NO ischemic preconditioning

Detailed Description

The study cohort was randomly divided into two groups. One group received remote ischemic preconditioning one day before partial nephrectomy, while the other group underwent partial nephrectomy directly. The degree of acute renal injury on the operated side was compared between the two groups

• Study Type: Interventional
• Enrollment (Estimated): 174
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Fangjian Zhou, professor; Phone Number: 020-87343865; Email: zhoufj@sysucc.org.cn

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510000
      • 651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China Sun Yat-sen University Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients who are scheduled to undergo partial nephrectomy, with no specific surgical procedure limitation, including laparoscopic surgery, robot-assisted surgery, and open surgery
• Aged 18 to 80

• Possess good organ function status: sufficient organ function (based on the normal values of the clinical trial center)

  1. Blood routine test: WBC≥3.5×10^9/L, absolute neutrophil count ≥1.5×10^9/L, PLT≥75.0×10^9/L, HGB≥80g/L;
  2. Liver function: Total bilirubin ≤1.5×upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN;

Exclusion Criteria:

• The anesthesiologist assesses that the patient cannot tolerate general anesthesia surgery
• Individuals with severe cardiovascular and cerebrovascular diseases, uncontrolled hypertension, and diabetes
• Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m²
• Horseshoe kidney
• Solitary kidney
• Pregnant women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental : Ischemic preconditioning; One day before the surgery, use a sphygmomanometer to apply pressure to the patient's upper limb to 200mmHg for 5 minutes, then reduce the pressure to 0mmHg for 5 minutes, repeating this process for a total of 3 cycles. On the second day, perform a routine partial nephrectomy	Procedure: Ischemic preconditioning; One day before the surgery, use a sphygmomanometer to apply pressure to the patient's upper limb to 200mmHg for 5 minutes, then reduce the pressure to 0mmHg for 5 minutes, repeating this process for a total of 3 cycles. On the second day, perform a routine partial nephrectomy
Active Comparator: Comparator : No ischemic preconditioning; Routine partial nephrectomy	Procedure: NO ischemic preconditioning; Routine partial nephrectomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AIRD spectrum score based on the patient's preoperative creatinine level and postoperative peak creatinine level	The AIRD spectrum score was defined as: (observed peak SCr - SCr ideal-peak)/(SCr worstcase-peak - SCr ideal-peak） The range of this indicator should be between 0 and 1, with 0 and 1 representing two extreme situations. 0 indicates that the kidney on the operated side is completely undamaged, while 1 indicates that the kidney on the operated side has completely lost its function.	2 weeks after partial nephrectomy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recovery from ischemia based on the changes in creatinine levels before and after the partial nephrectomy and volume retention rate after the partial nephrectomy	Recovery from ischemia = (%GFR saved)/(%parenchymal mass preserved)	3 month after surgery

Collaborators and Investigators

• Sponsor: Sun Yat-sen University
• Investigators: Principal Investigator: Fangjian Zhou, professor, Sun Yat-sen University Cancer Center (SYSUCC)

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: March 15, 2026
• First Submitted That Met QC Criteria: March 23, 2026
• First Posted (Actual): March 27, 2026

Study Record Updates

• Last Update Posted (Actual): March 27, 2026
• Last Update Submitted That Met QC Criteria: March 23, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Partial nephrectomy; Acute kidney injury; Ischemic preconditioning; Renal Function Abnormal
• Additional Relevant MeSH Terms: Urogenital Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Renal Insufficiency; Urologic Neoplasms; Carcinoma; Kidney Neoplasms; Acute Kidney Injury; Carcinoma, Renal Cell; Investigative Techniques; Therapeutics; Ischemic Preconditioning
• Other Study ID Numbers: B2026-114

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No